Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models

Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19. doi: 10.1128/AAC.00710-19. Print 2019 Aug.

Abstract

Pseudomonas aeruginosa is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung infection models. MEDI3902 prophylaxis or treatment was protective in both acute models and exhibited enhanced activity when combined with a subtherapeutic dose of meropenem. These findings further support MEDI3902 for the prevention or treatment of serious P. aeruginosa infections.

Keywords: Pseudomonas aeruginosa; bloodstream infections; immunotherapy; pneumonia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Bispecific / therapeutic use*
  • Bacteremia / drug therapy
  • Bacteremia / microbiology
  • Bacteremia / therapy
  • Immunotherapy
  • Meropenem / therapeutic use
  • Pneumonia / drug therapy*
  • Pneumonia / microbiology
  • Pneumonia / therapy
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas Infections / therapy
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / pathogenicity*
  • Rabbits
  • Treatment Outcome

Substances

  • Antibodies, Bispecific
  • gremubamab
  • Meropenem